Discontinued — last reported Q1 '20
Merck & Co. Equity Securities Without Readily Determinable Fair Value decreased by 0.4% to $831.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 3.7%, from $863.00M to $831.00M. Over 5 years (FY 2020 to FY 2025), Equity Securities Without Readily Determinable Fair Value shows an upward trend with a 7.2% CAGR.
An increase suggests a strategic shift toward private market investments or long-term partnerships with non-public entities.
This represents the carrying amount of equity investments for which a readily determinable market price is not available...
Common for large corporations with active corporate venture capital or strategic partnership programs.
equity_securities_without_fair_value| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $694.00M | $578.00M | $596.00M | $643.00M | $671.00M | $705.00M | $832.00M | $942.00M | $949.00M | $863.00M | $832.00M | $851.00M | $936.00M | $848.00M | $863.00M | $872.00M | $870.00M | $834.00M | $831.00M |
| QoQ Change | — | -16.7% | +3.1% | +7.9% | +4.4% | +5.1% | +18.0% | +13.2% | +0.7% | -9.1% | -3.6% | +2.3% | +10.0% | -9.4% | +1.8% | +1.0% | -0.2% | -4.1% | -0.4% |
| YoY Change | — | — | — | — | -3.3% | +22.0% | +39.6% | +46.5% | +41.4% | +22.4% | +0.0% | -9.7% | -1.4% | -1.7% | +3.7% | +2.5% | -7.1% | -1.7% | -3.7% |
We use cookies for analytics. See our Privacy and Cookie Policy.